NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Stock Has Average Price Target of $7.33 According to Analysts

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has been assigned an average rating of “Hold” from the five analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $7.33.

NMTC has been the subject of a number of research reports. Maxim Group set a $5.00 price target on NeuroOne Medical Technologies and gave the company a “buy” rating in a research note on Friday, August 14th. Weiss Ratings downgraded NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st.

Insider Activity

In other news, insider David Wambeke bought 33,333 shares of the stock in a transaction dated Thursday, August 27th. The stock was purchased at an average cost of $2.01 per share, for a total transaction of $66,999.33. Following the transaction, the insider owned 199,999 shares of the company’s stock, valued at $401,997.99. The trade was a 20.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 11.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NMTC. Bard Associates Inc. bought a new stake in NeuroOne Medical Technologies in the second quarter worth $929,000. BlackRock Inc. purchased a new stake in NeuroOne Medical Technologies during the second quarter valued at $76,000. Finally, Susquehanna International Group LLP bought a new position in NeuroOne Medical Technologies during the second quarter valued at $41,000. 16.07% of the stock is owned by hedge funds and other institutional investors.

NeuroOne Medical Technologies Stock Up 4.0%

NMTC opened at $1.00 on Tuesday. The firm has a 50-day simple moving average of $1.49 and a two-hundred day simple moving average of $2.75. NeuroOne Medical Technologies has a 52 week low of $0.95 and a 52 week high of $6.12. The company has a market capitalization of $9.11 million, a PE ratio of -1.05 and a beta of 0.77.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). The firm had revenue of $1.97 million for the quarter, compared to analysts’ expectations of $2.17 million. NeuroOne Medical Technologies had a negative net margin of 71.50% and a negative return on equity of 128.12%. As a group, sell-side analysts expect that NeuroOne Medical Technologies will post -0.39 earnings per share for the current year.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation is a medical device company focused on developing and commercializing technologies for recording, monitoring, and treating neurological disorders. Its products are designed for use by neurosurgeons and neurologists in procedures involving the brain and nervous system, including the diagnosis and treatment of epilepsy and other neurological conditions.

The company’s product portfolio includes the Evo cortical and stereoelectroencephalography (sEEG) electrode systems, which are used to record electrical activity in the brain.